Skip to main content
    P

    Precision BioSciences Inc (DTIL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.28
    -0.28 (-3.77%)

    Market Cap: $288.76M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Precision BioSciences Inc (DTIL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Precision BioSciences reported revenue of $34.26M for the fiscal year ended Dec 31, 2025, down 50.1% from the year before. That year, net income was -$45.72M with a net margin of -133.4%, operating cash flow was -$65.84M and free cash flow was -$65.93M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.59M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $7.01M, a compound annual rate of 19.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$34.26M-50.1%100.0%-152.2%-133.4%
    Dec 2024$68.70M+41.0%100.0%-38.1%10.4%
    Dec 2023$48.73M+94.1%100.0%-89.8%-125.8%
    Dec 2022$25.10M-78.3%100.0%-248.3%-444.8%
    Dec 2021$115.53M+375.7%100.0%-34.1%-26.5%
    Dec 2020$24.29M+9.2%100.0%-452.2%-445.5%
    Dec 2019$22.24M+104.3%100.0%-392.1%-443.2%
    Dec 2018$10.88M+67.8%100.0%-440.2%-423.0%
    Dec 2017$6.48M-7.6%100.0%-338.9%-325.4%
    Dec 2016$7.01MN/A100.0%-125.8%-117.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$34.26M$68.70M$48.73M$25.10M$115.53M$24.29M$22.24M$10.88M$6.48M$7.01M
    Gross profit$34.26M$68.70M$48.73M$25.10M$115.53M$24.29M$22.24M$10.88M$6.48M$7.01M
    Research and development$54.17M$59.56M$53.38M$46.12M$115.24M$98.06M$82.42M$45.12M$20.32M$9.10M
    Operating income-$52.15M-$26.16M-$43.74M-$62.31M-$39.38M-$109.83M-$87.20M-$47.91M-$21.97M-$8.83M
    Net income-$45.72M$7.17M-$61.32M-$111.64M-$30.60M-$108.18M-$98.55M-$46.04M-$21.10M-$8.25M
    EBITDA-$41.43M$7.40M-$34.94M-$53.87M-$26.58M-$100.02MN/A-$43.68M-$20.42M-$8.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$10.84M$34.20M$13.00K$18.00K$29.00K$638.00K$576.00K$49.90M$17.58M$7.04M
    Gross profit$0$0$10.84M$34.20M$13.00K$18.00K$29.00K$638.00K$576.00K$49.90M$17.58M$7.04M
    Operating income-$20.43M-$19.16M-$9.07M$12.51M-$20.67M-$21.88M-$22.11M-$24.85M-$21.27M$24.15M-$4.19M-$14.89M
    Net income-$7.59M-$32.65M-$18.44M$20.13M-$21.77M-$23.52M-$20.57M-$17.75M-$16.43M$32.75M$8.59M-$16.29M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $23.91M by $86.91M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$154.42M$136.39M$159.78M$238.17M$211.50M$150.16M$235.23M$138.60M$72.68M$98.41M
    Current assets$118.74M$94.99M$136.36M$199.10M$161.75M$105.56M$193.67M$115.67M$64.33M$94.40M
    Cash and equivalents$110.82M$85.90M$116.68M$189.58M$143.66M$89.80M$180.89M$103.19M$62.80M$93.42M
    Total liabilities$62.17M$80.00M$140.92M$177.74M$120.33M$105.73M$96.92M$98.64M$99.05M$103.16M
    Short-term debt$1.51M$1.32M$22.41M$0$1.82M$1.93M$6.83M$3.25M$1.51MN/A
    Long-term debt$22.40M$22.32M$0$22.22M$2.48MN/AN/AN/AN/AN/A
    Shareholder equity$92.25M$56.39M$18.86M$60.43M$91.17M$44.42M$138.31M$39.95M-$26.37M-$4.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$120.38M$125.92M$143.89M$154.42M$93.51M$108.93M$124.41M$136.39M$153.26M$165.80M$184.74M$159.78M
    Total liabilities$68.60M$80.63M$67.79M$62.17M$76.88M$74.87M$75.07M$80.00M$88.39M$91.09M$147.53M$140.92M
    Cash and equivalents$81.70M$86.08M$99.37M$110.82M$44.87M$62.24M$77.22M$85.90M$98.75M$123.57M$137.77M$116.68M
    Shareholder equity$51.77M$45.29M$76.10M$92.25M$16.63M$34.05M$49.34M$56.39M$64.87M$74.71M$37.21M$18.86M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$65.84M-$58.45M-$84.11M-$45.75M-$10.85M-$87.39M-$71.02M-$51.72M-$24.17M$92.27M
    Capital expenditures$85.00K$250.00K$1.96M$3.32M$5.05M$5.03M$24.67M$15.68M$5.57M$2.08M
    Free cash flow-$65.93M-$58.70M-$86.07M-$49.07M-$15.91M-$92.42M-$95.68M-$67.40M-$29.73M$90.20M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/AN/A$12.43M
    Share repurchasesN/AN/AN/AN/AN/AN/A$2.62MN/AN/AN/A
    Investing cash flow-$634.00K-$215.00K$5.83M-$3.32M-$5.80M-$5.03M-$24.67M-$15.66M-$5.51M-$2.08M
    Financing cash flow$95.16M$50.45M$5.39M$94.98M$70.52M$1.33M$173.37M$107.78M-$937.00K-$12.38M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.13M-$13.44M-$11.94M-$11.25M-$15.27M-$20.27M-$19.05M-$18.68M-$5.91M-$14.87M-$18.98M-$8.42M
    Capital expendituresN/AN/A$18.00K$19.00K$15.00K$2.00K$64.00K$97.00K$39.00K$28.00K$86.00K$26.00K
    Free cash flowN/AN/A-$11.96M-$11.27M-$15.29M-$20.27M-$19.12M-$18.78M-$5.95M-$14.90M-$19.07M-$8.45M
    Last 12 quarters

    Frequently Asked Questions About DTIL

    What is Precision BioSciences' annual revenue?

    Precision BioSciences reported revenue of $34.26M for the fiscal year ended Dec 31, 2025.

    How fast is Precision BioSciences' revenue growing?

    Revenue was down 50.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.9%.

    Is Precision BioSciences profitable?

    No. Precision BioSciences reported net income of -$45.72M for the fiscal year ended Dec 31, 2025, with a net margin of -133.4%.

    How much free cash flow does DTIL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$65.84M minus capital expenditures of $85.00K produced free cash flow of -$65.93M.

    How much debt does Precision BioSciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $22.40M, short-term debt of $1.51M and cash and equivalents of $110.82M.